CTOs on the Move


 
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.angion.com
  • 456 Montgomery Street Suite 1200
    San Francisco, CA USA 94104
  • Phone: 415.655.4899

Executives

Name Title Contact Details
David Upchurch
Vice President of Technical Operations Profile

Funding

Angion raised $25M on 02/09/2021

Similar Companies

AmnioLife

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.

Gotham Therapeutics

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.

Complexa Inc

Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.

Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.

B-Bridge International

B-Bridge International is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.